Josep Gamez and Maria Salvado presented the TTR Amyloidosis Phase IIa in Vancouver
From 15 to 21 of April took place in Vancouver, BC, Canada the 68th Annual Meeting of American Academy of Neurology, the most important meeting about neurology in the world.
This year, the neurologists Josep Gamez (Ph, MD) and Maria Salvdo (MD) presented the TTR Amyloidosis Phase IIa, a clinical trial in humans to evaluate the efficacy and safety of an innovative oral therapy for transthyretin amyloidosis (TTA), a rare disease that affects the peripheral nervous system and heart.
The trial of compound SOM0226 (tolcapone), a reprofiled drug developed entirely by the biopharmaceutical company SOM Biotech , was initiated a year ago under the coordination of Dr. Josep Gamez, head of the Peripheral Nervous System Research Unit of the Vall d'Hebron Research Institute (VHIR). 17 subjects participated in the trial, including patients affected by the polyneuropathic variant of the disease and healthy individuals.
“We have shown that compound SOM226 has a high potential to stabilize protein transthyretin in patients and therefore, it can slow down the progression of this invalidating minority disease”, says Dr. Gamez.
See more INFO